{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:51:40Z","timestamp":1757699500392,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11899-022-00675-3","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T11:02:59Z","timestamp":1661598179000},"page":"286-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bispecific Antibodies for the Treatment of Multiple Myeloma"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-2418","authenticated-orcid":false,"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Streeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahrettin","family":"Covut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"675_CR1","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica [Internet]. 2016;101(4):396\u2013406. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27033237","DOI":"10.3324\/haematol.2015.129189"},{"key":"675_CR2","doi-asserted-by":"crossref","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia [Internet]. 2018 Feb 19;32(2):252\u201362. Available from: http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.329","DOI":"10.1038\/leu.2017.329"},{"key":"675_CR3","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med [Internet]. 2016;375(14):1319\u201331. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1607751","DOI":"10.1056\/NEJMoa1607751"},{"key":"675_CR4","doi-asserted-by":"crossref","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New Engl J Med [Internet]. 2016 Aug 25;375(8):754\u201366. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1606038","DOI":"10.1056\/NEJMoa1606038"},{"key":"675_CR5","doi-asserted-by":"publisher","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood [Internet]. 2020 Aug 20;136(8):936\u201345. Available from: https:\/\/doi.org\/10.1182\/blood.2020005288","DOI":"10.1182\/blood.2020005288"},{"key":"675_CR6","doi-asserted-by":"crossref","unstructured":"Viola D, Dona A, Gunes EG, Troadec E, Wu X, Branciamore S, et al. Immune mediated mechanisms of resistance to daratumumab. Blood [Internet]. 2018;132(Suppl 1):3201 LP \u2013 3201. Available from: http:\/\/www.bloodjournal.org\/content\/132\/Suppl_1\/3201.abstract","DOI":"10.1182\/blood-2018-99-117441"},{"key":"675_CR7","doi-asserted-by":"crossref","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol [Internet]. 2011;186(3):1840\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21187443","DOI":"10.4049\/jimmunol.1003032"},{"key":"675_CR8","doi-asserted-by":"crossref","unstructured":"Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology [Internet]. 2018 Jul 23;7(10):e1486948\u2013e1486948. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30288349","DOI":"10.1080\/2162402X.2018.1486948"},{"key":"675_CR9","doi-asserted-by":"crossref","unstructured":"Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia [Internet]. 2021;35(1):189\u2013200. Available from: http:\/\/www.nature.com\/articles\/s41375-020-0810-4","DOI":"10.1038\/s41375-020-0810-4"},{"issue":"6","key":"675_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/cancers13061353","volume":"13","author":"A D\u00edaz-Tejedor","year":"2021","unstructured":"D\u00edaz-Tejedor A, Lorenzo-Mohamed M, Puig N, Garc\u00eda-Sanz R, Mateos MV, Garayoa M, et al. Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers (Basel). 2021;13(6):1353.","journal-title":"Cancers (Basel)"},{"key":"675_CR11","doi-asserted-by":"crossref","unstructured":"Dhodapkar M v. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016;128(23):2599\u2013606.","DOI":"10.1182\/blood-2016-09-692954"},{"issue":"1","key":"675_CR12","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.26010","volume":"96","author":"R Cornell","year":"2021","unstructured":"Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, et al. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021;96(1):E5-8.","journal-title":"Am J Hematol"},{"key":"675_CR13","doi-asserted-by":"crossref","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New Engl J Med [Internet]. 2019 May 2;380(18):1726\u201337. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1817226","DOI":"10.1056\/NEJMoa1817226"},{"key":"675_CR14","doi-asserted-by":"publisher","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. The Lancet [Internet]. 2021;398(10297):314\u201324. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"675_CR15","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine [Internet]. 2021;384(8):705\u201316. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2024850","DOI":"10.1056\/NEJMoa2024850"},{"key":"675_CR16","doi-asserted-by":"publisher","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. New Engl J Med [Internet]. 2017;376(9):836\u201347. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1609783","DOI":"10.1056\/NEJMoa1609783"},{"key":"675_CR17","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood [Internet]. 2018;131(14):1522\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29358182","DOI":"10.1182\/blood-2017-08-798322"},{"key":"675_CR18","doi-asserted-by":"publisher","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia [Internet]. 2020;34(4):985\u20131005. Available from: https:\/\/doi.org\/10.1038\/s41375-020-0734-z","DOI":"10.1038\/s41375-020-0734-z"},{"issue":"3","key":"675_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136.","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"675_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"675_CR21","doi-asserted-by":"crossref","unstructured":"Labrijn AF, Meesters JI, de Goeij BECG, van den Bremer ETJ, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proceedings of the National Academy of Sciences. 2013;110(13):5145\u201350. Interesting publication on the development and production methodology of bispecific antibodies and the process of Fab-arm exchange","DOI":"10.1073\/pnas.1220145110"},{"issue":"8","key":"675_CR22","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048\u201360.","journal-title":"Clin Cancer Res"},{"key":"675_CR23","doi-asserted-by":"crossref","unstructured":"Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. Cancers (Basel). 2020 Jun 5;12(6).","DOI":"10.3390\/cancers12061473"},{"key":"675_CR24","doi-asserted-by":"crossref","unstructured":"Maus M v, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26\u201331.","DOI":"10.1158\/2326-6066.CIR-13-0006"},{"key":"675_CR25","doi-asserted-by":"publisher","unstructured":"Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia [Internet]. 2017;31(8):1743\u201351. Available from: https:\/\/doi.org\/10.1038\/leu.2016.388. Preclinical development of AMG-420.","DOI":"10.1038\/leu.2016.388"},{"key":"675_CR26","doi-asserted-by":"publisher","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti\u2013B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol [Internet]. 2020;38(8):775\u201383. Available from: https:\/\/doi.org\/10.1200\/JCO.19.02657. First study of bispecific construct in multiple myeloma that demonstrated significant efficacy but some issues with tolerability and cytokine release syndrome, as well as logistical challenges as the drug required continuous IV infusion.","DOI":"10.1200\/JCO.19.02657"},{"issue":"17","key":"675_CR27","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","volume":"4","author":"SF Cho","year":"2020","unstructured":"Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195\u2013207.","journal-title":"Blood Adv"},{"key":"675_CR28","doi-asserted-by":"crossref","unstructured":"Harrison S, Minnerna M, Lee H, Spencer A, Kapoor P, Madduri D, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM). In: American Society of Hematology. 2021.","DOI":"10.1182\/blood-2020-134063"},{"issue":"18","key":"675_CR29","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell\u2013redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538\u201349.","journal-title":"Blood Adv"},{"key":"675_CR30","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374. Phase I portion of the clinical trial evaluating the safety and efficacy of teclistimab, with data that are supporting its regulatory application.","DOI":"10.1016\/S0140-6736(21)01338-6"},{"issue":"Supplement 1","key":"675_CR31","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2021-147915","volume":"138","author":"P Moreau","year":"2021","unstructured":"Moreau P, Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel J, et al. Updated results from MajesTEC-1: phase 1\/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):896\u2013896.","journal-title":"Blood"},{"key":"675_CR32","doi-asserted-by":"publisher","unstructured":"Karwacz K, Hooper AT, Chang CPB, Krupka H, Chou J, Lam V, et al. Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: preclinical rationale for therapeutic combinations. Cancer Research [Internet]. 2020 Aug 15;80(16_Supplement):4557. Available from: https:\/\/doi.org\/10.1158\/1538-7445.AM2020-4557","DOI":"10.1158\/1538-7445.AM2020-4557"},{"key":"675_CR33","doi-asserted-by":"publisher","unstructured":"Sebag M, Raje NS, Bahlis NJ, Costello C, Dholaria B, Solh M, et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from Magnetismm-1. Blood [Internet]. 2021;138(Supplement 1):895. Available from:https:\/\/doi.org\/10.1182\/blood-2021-150519","DOI":"10.1182\/blood-2021-150519"},{"key":"675_CR34","doi-asserted-by":"publisher","unstructured":"Bahlis NJ, Raje NS, Costello C, Dholaria BR, Solh MM, Levy MY, et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J Clin Oncol [Internet]. 2021 May 20;39(15_suppl):8006. Available from:https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8006","DOI":"10.1200\/JCO.2021.39.15_suppl.8006"},{"key":"675_CR35","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.1016\/S2152-2650(21)01978-9","volume":"21","author":"M Levy","year":"2021","unstructured":"Levy M, Bahlis N, Raje N, Costello C, Dholaria B, Solh M, et al. MM-379: MagnetisMM-1: a study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM). Clin Lymphoma Myeloma Leuk. 2021;21:S439.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"675_CR36","doi-asserted-by":"publisher","unstructured":"Buelow B, Choudry P, Clarke S, Dang K, Davison L, Force Aldred S, et al. Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. J Clin Oncol [Internet]. 2018;36(15_suppl):8034. Available from:https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.8034","DOI":"10.1200\/JCO.2018.36.15_suppl.8034"},{"issue":"Supplement 1","key":"675_CR37","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2021-150757","volume":"138","author":"S Kumar","year":"2021","unstructured":"Kumar S, D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Bueno OF, et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):900\u2013900.","journal-title":"Blood"},{"issue":"Supplement 1","key":"675_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-139893","volume":"136","author":"C Rodriguez","year":"2020","unstructured":"Rodriguez C, D\u2019Souza A, Shah N, Voorhees PM, Buelow B, Vij R, et al. Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in relapsed\/refractory multiple myeloma. Blood. 2020;136(Supplement 1):43\u20134.","journal-title":"Blood"},{"issue":"5","key":"675_CR39","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5(5):1291\u2013304.","journal-title":"Blood Adv"},{"key":"675_CR40","doi-asserted-by":"crossref","unstructured":"Zonder J, Richter J, Bumma N, Brayer J, Hoffman J, Bensinger W, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM). Am Soc Hematol. 2021;","DOI":"10.1182\/blood-2021-144921"},{"key":"675_CR41","doi-asserted-by":"crossref","unstructured":"Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. 2013 Nov;18(6):348\u201351. Detailed study on GPRC5D which is proving to be a novel target for multiple myeloma.","DOI":"10.1179\/1607845413Y.0000000079"},{"issue":"8","key":"675_CR42","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"issue":"15","key":"675_CR43","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, Li Y, Tornetta M, Babich A, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343.","journal-title":"Blood"},{"issue":"Supplement 1","key":"675_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood-2021-146868","volume":"138","author":"AY Krishnan","year":"2021","unstructured":"Krishnan AY, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodriguez-Otero P, et al. Updated phase 1 results from MonumenTAL-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):158\u2013158.","journal-title":"Blood"},{"issue":"Supplement 1","key":"675_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/blood-2021-148813","volume":"138","author":"A Chari","year":"2021","unstructured":"Chari A, Hari P, Bahlis NJ, Mateos MV, van de Donk NWCJ, Dholaria B, et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):161\u2013161.","journal-title":"Blood"},{"issue":"3","key":"675_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383\u201395.","journal-title":"Cancer Cell"},{"key":"675_CR47","doi-asserted-by":"publisher","unstructured":"Stewart AK, Krishnan AY, Singhal S, Boccia R v, Patel MR, Niesvizky R, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer Journal [Internet]. 2019;9(2):17. Available from: https:\/\/doi.org\/10.1038\/s41408-019-0178-8","DOI":"10.1038\/s41408-019-0178-8"},{"issue":"Supplement 1","key":"675_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Supplement 1):157\u2013157.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00675-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00675-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00675-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T05:08:37Z","timestamp":1669871317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00675-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00675-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2022,8,27]]},"assertion":[{"value":"8 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SRG has consulted for Janssen Pharmaceuticals, Sanofi-Genzyme, Wugen Inc., and Oncovalent Theapeutics, and received travel funding from Adaptive Biosciences. SS and FC declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}